15 alternatives ranked by AI visibility score. Category: Metabolic Disease.
Verdiva Bio raised $200M in 2025 for next-generation oral GLP-1 receptor agonists designed to match injectable semaglutide efficacy with once-daily oral dosing for obesity and type 2 diabetes.
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (
Umoja Biopharma is developing an in vivo CAR-T cell therapy platform that circumvents the costly and time-consuming ex vivo manufacturing process that limits current CAR-T therapie
Finch Therapeutics is a clinical-stage biotechnology company founded in 2015 that develops microbiome medicines targeting the relationship between the gut microbiome and systemic d
Microbiotica applies genomics and machine learning to map the gut microbiome's causal role in disease, then develops live biotherapeutic products (LBPs) targeting the specific bact
Beam Therapeutics is a genetic medicines company founded in 2017 by base editing pioneers David Liu, J. Keith Joung, and Feng Zhang, having raised over $600M and gone public on Nas
Profluent Bio is an AI protein design company founded in 2022 by former Meta AI researcher Ali Madani, raising $35M in seed and Series A funding. The company trains large generativ
Infant Bacterial Therapeutics (IBT) is a Swedish biopharma company developing Lactobacillus reuteri DSM17938 — a probiotic bacterial strain — as a regulated drug (live biotherapeut
Aevice Health develops wearable respiratory monitoring technology that uses AI to analyze breath sounds captured continuously from a chest-worn device. The AeviceMD system detects